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AbstrAct
Introduction Respiratory tract infections (RTIs) are the 
most common reason for primary care (PC) consultations 
and for antibiotic prescribing and use. The majority of RTIs 
have a viral aetiology however, and antibiotic consumption 
is ineffective and unnecessary. Inappropriate antibiotic use 
contributes greatly to antibiotic resistance (ABR) leading to 
complications, increased adverse events, reconsultations 
and costs. Improving antibiotic consumption is thus crucial 
to containing ABR, which has become an urgent priority 
worldwide. We will systematically review the evidence 
about interventions aimed at improving the quality of 
antibiotic prescribing and use for acute RTI.
Methods and analysis We will include primary peer-
reviewed and grey literature of studies conducted on in-
hours and out-of-hours PC patients (adults and children): 
(1) randomised controlled trials (RCTs), quasi-RCTs and/
or cluster-RCTs evaluating the effectiveness, feasibility 
and acceptability of patient-targeted and clinician-
targeted interventions and (2) RCTs and other study 
designs evaluating the effectiveness of public campaigns 
and regulatory interventions. We will search MEDLINE 
(EBSCOHost), EMBASE (Elsevier), the Cochrane Library 
(Wiley), CINHAL (EBSCOHost), PsychINFO (EBSCOHost), 
Web of Science, LILACS (Latin American and Caribbean 
Literature on Health Sciences), TRIP (Turning Research Into 
Practice) and  opensgrey. eu without language restriction. 
We will also search the reference lists of included studies 
and relevant reviews. Primary outcomes include the 
rates of (guideline-recommended) antibiotics prescribed 
and/or used. Secondary outcomes include immediate or 
delayed use of antibiotics, and feasibility and acceptability 
outcomes. We will assess study eligibility and risk of bias, 
and will extract data. Data permitting, we will perform 
meta-analyses.
Ethics and dissemination This is a systematic review 
protocol and so formal ethical approval is not required. We 
will not collect confidential, personal or primary data. The 
findings of this review will be disseminated at national and 
international scientific meetings.
Trial registration number  PROSPERO trial 
(CRD42017035305).
IntroductIon
Antibiotic resistance (ABR) is a major threat 
to public health globally.1 Drug-resistant infec-
tions lead to a higher risk of worse clinical 
outcomes and death than non-drug-resis-
tant infections.2 It is estimated that if ABR 
continues to rise, as it has in the last decades, 
10 million people would die yearly from 
drug-resistant infections. This could cause a 
global economic loss of US$60–100 trillion 
between now and 2050.3 Antibiotic consump-
tion, particularly inappropriate drug use, is 
the main and modifiable driver of ABR.4 The 
extent of antibiotic use has been consistently 
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Protocol
Strengths and limitations of this study
 ► First ‘back-to-back’ systematic review assessing 
both (1) healthcare professional and patient-
targeted interventions and (2) public campaigns 
and regulatory interventions which aim to improve 
prescribing quality and use of antibiotics for acute 
respiratory tract infection.
 ► First systematic review with a broad scope of 
international evidence from peer-reviewed and grey 
literature including all types of such interventions, 
expanded to adults and children, and in-hours and 
out-of-hours care.
 ► Searching a large number of sources and searching 
without language restrictions will add to the 
comprehensiveness of this review.
 ► The quality of studies and the significant 
heterogeneity of results might limit the performance 
of meta-analyses and may challenge the 
interpretation of findings.
 ► Our results will help healthcare professionals, 
policy-makers and public health researchers make 
informed decisions about the interventions that 
provide most benefits in optimising the quality of 
prescribing and use of antibiotics and may help 
design such interventions in the future.
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associated with the rate of ABR at the individual, commu-
nity and national levels.5 6
Most antibiotics used in humans are administered in 
primary care (PC). In Europe, 80%–90% of all antibiotics 
are prescribed in primary ambulatory care,6 7 whereas in 
the USA at least 70% of patients visiting their family physi-
cian receive antibiotics.7 Antibiotics are dispensed or sold 
inappropriately too, and they are taken incorrectly by the 
majority of consumers.8 Most of this inappropriate use 
is still common for respiratory tract infections (RTIs),9 
and RTIs are a leading cause of patient encounters in 
general practice.10 The common cold, acute sore throat, 
pharyngitis and tonsillitis, acute otitis media, rhinitis, 
acute sinusitis, laryngitis and acute bronchitis are the 
most common acute RTIs. These are normally self-lim-
iting, and since they often have a viral cause, they mostly 
improve without antibiotic therapy.11 However, self-medi-
cation with antibiotics is also most common for colds and 
upper RTIs in the USA12–14 and Europe.15 Inappropriate 
use of antibiotics often lead to increased incidence of 
adverse events, reconsultations, resource use, RTI compli-
cations and costs, and ultimately contribute to bacterial 
resistance.4
Furthermore, the inappropriate use of antibiotics is 
highly influenced by human behaviour at many levels of 
society. Many complex factors contribute greatly to the 
problem, including lack of knowledge and concern,16 
underestimation of ABR17 and patients’ expectations for 
antibiotics, as well as the pressure on physicians to meet 
these expectations.18 In addition, medicalising with anti-
biotics encourages patients to revisit and expect similar 
antibiotics behaviour in future episodes.19
There is a fast-growing body of literature about inter-
ventions designed to improve the quality of prescribing 
and use of antibiotics for RTIs. Multifaceted interven-
tions, interventions involving physicians and pharmacists, 
and patient education are more likely to reduce antibiotic 
prescribing rates and increase the use of recommended 
antibiotics, as well as improve antibiotic consumption.20 21 
Lowering antibiotic dispensing at general practices can 
also reduce ABR22 23 and has positive effects on seeking 
behaviour for RTIs (eg, change in expecting antibi-
otics).24 Various systematic reviews also show that some of 
the outpatient interventions can safely improve or reduce 
antibiotic prescribing and use.25–28 Yet WHO Global 
Strategy to contain ABR recognises that isolated inter-
ventions have little impact on improving antibiotic use.29 
In many countries, interventions are increasingly being 
integrated in system-level and population-level strate-
gies including public health campaigns and regulatory 
interventions to translate knowledge and recommenda-
tions into practice,30 to change antibiotics behaviour and 
to reduce ABR.31–34 This systematic review will appraise 
the existing evidence and estimate the effectiveness of 
interventions aiming to improve the quality of antibiotic 
prescribing and use for acute RTIs in PC. Our second 
objective is to assess the feasibility and acceptability of 
patient-targeted and clinician-targeted interventions. We 
also expect to identify the intervention components that 
are most strongly associated with effectiveness.
We hypothesise that interventions aimed at improving 
the quality of antibiotic prescribing and use for RTIs: (1) 
are more effective in reducing inappropriate antibiotic 
prescribing, dispensing by healthcare professionals (clini-
cians and/or pharmacists) and use by patients, their carers 
or parents when multiple components are integrated to 
target both patients and healthcare professionals and (2) 
work better at reducing antibiotic use-related problems 
when they target healthcare professionals and patients 
by means of public campaigns. We also hypothesise that 
such interventions are even more effective in making a 
step change when they are implemented at the system level 
by means of regulatory measures. In addition, knowing 
the feasibility and acceptability of patient-targeted and 
clinician-targeted interventions may help explain their 
comparative effectiveness and guide their implementa-
tion in practice.
Methods
Our systematic review protocol follows the guidance 
for the Preferred Reporting Items for Systematic 
reviews and Meta-analyses for Protocols (PRISMA-P) 
(see online supplementary file 1),35 and it is registered 
on PROSPERO (CRD42017035305).
design
Systematic review of primary peer-reviewed and grey liter-
ature.
review questions
We will guide this systematic review with the following 
questions:
 ► What is the (comparative) effectiveness of 
interventions to improve antibiotic use on the quality 
of antibiotic prescribing and use in PC patients with 
acute RTI?
 ► What is the feasibility and acceptability of patient-
targeted and clinician-targeted interventions to 
improve antibiotic use on the quality of antibiotic 
prescribing and use in patients with acute RTI in PC 
general practice?
These questions will also guide the identification of the 
interventions’ components that appear to be associated 
with success.
eligibility criteria
Types of participants
We will include studies examining both adults and chil-
dren of all ages presenting to PC settings with a common 
acute RTI. The studies might involve:
 ► adult patients and/or paediatric patients (together 
with their parents) with an acute RTI;
 ► carers or parents of patients with an acute RTI;
 ► healthcare providers of patients with an acute RTI 
including physicians (eg, paediatricians and family 
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physicians) of in-hours and out-of-hours ambulatory 
care services and/or pharmacists.
RTIs are labelled as acute if there is a sudden onset of 
symptoms lasting <4 weeks without diagnosis regardless of 
whether or not antibiotics are being prescribed.36 RTIs 
are classified as upper RTIs or lower RTIs. Upper RTIs 
include acute pharyngitis, nasopharyngitis, rhinitis and 
common cold, otitis media (acute and chronic), acute 
mastoiditis, acute sinusitis, croup (laryngotracheobron-
chitis), epiglottitis and diphtheria.37 Lower RTIs include 
bronchitis (acute and chronic), bronchiolitis, influenza, 
chronic recurrent cough, pneumonia, acute exacerba-
tion of chronic obstructive pulmonary disease (COPD), 
and acute exacerbation of bronchiectasis.37–39 The most 
common acute RTIs include the common cold, acute 
cough, acute sore throat, pharyngitis and tonsillitis, acute 
otitis media, rhinitis, acute sinusitis, laryngitis and acute 
bronchitis.
We will exclude studies of exacerbations of COPD and/
or other pre-existing chronic pulmonary diseases and 
studies involving inpatients.
Types of interventions and comparators
We will include studies that evaluate interventions rele-
vant to improving antibiotic prescribing and use for RTIs 
based on previous reviews.26 27 The interventions vary 
according to the behaviours they try to influence. These 
include modification of self-medication and expectations 
in consumers (patients and general public) or reduction 
of prescribing and dispensing by healthcare profes-
sionals (clinicians and pharmacists). Through changing 
behaviour, these aim to improve patient outcomes while 
limiting resistance, complications, adverse effects and 
costs. They might take the format of single or multifac-
eted interventions and can be classified by the approach 
used to influence antibiotic use behaviour, for example, 
educational, clinical (eg, delayed prescribing and point 
of care) and system level strategies (eg, review/feed-
back).26 27 We will focus on:
 ► healthcare professional (clinicians and/or 
pharmacists) and patient-targeted interventions
 ► public campaigns: local, national and international 
awareness and ‘choosing wisely’ campaigns40 41
 ► regulatory interventions.
Comparators will include alternative interventions 
that also aim to improve antibiotic prescribing and use 
for RTIs including interventions consisting of one or 
multiple components, or usual care.
Healthcare professional interventions target clinicians 
(eg, paediatricians and family physicians, and nurses) 
or pharmacists, whereas patient-targeted interventions 
target patients with acute RTIs and/or their parents or 
carers. Public awareness campaigns are population-level 
strategies that target the general public. They are 
designed to raise public awareness and knowledge about 
antibiotic misuse through mass media such as television, 
radio, internet, posters, leaflets and newspapers.32 Their 
aim is to benefit the target population and/or the society 
altogether. Regulatory interventions are system-level 
strategies designed to outline a framework of require-
ments and legal practice of antibiotic use (eg, limiting 
, prescribing and/or dispensing).8 42 Their goal is to 
enforce decision-making to improve the use of antibiotics.
Types of outcome measures
We will extract primary and secondary outcomes to 
measure the effectiveness, feasibility and acceptability of 
interventions, regardless of the outcome measurement 
instruments used, the outcome measure (eg, prescribed 
individuals, prescriptions, items as numerators and 
patients with RTI or patient-years ‘at risk’ as denomina-
tors),43–45 their nature (objective or subjective) and time 
points.
effectiveness
Primary outcomes
For all interventions to improve antibiotic use, the effect 
of interventions on the quality of antibiotic prescribing 
and use will be measured by means of:
 ► rates and types of (any) antibiotics prescribed and/
or used for PC patients with acute RTI
 ► rates and types of guideline-recommended 
antibiotics prescribed for PC patients with acute RTI.
Secondary outcomes
For healthcare professional and patient-targeted inter-
ventions, the effect of interventions on the quality of 
antibiotic prescribing and use will be measured by means 
of:
 ► rates and types of antibiotics prescribed as immediate 
and delayed use;
 ► patients’ adherence to immediate and/or delayed 
prescribing;
 ► antibiotic resistance (eg, rates of patients with RTI with 
proven antibiotic resistant bacteria, and reduction of 
resistance as a result of the intervention);
 ► types and rates of medical complications (eg, 
emergency visits, hospital admissions due to possible 
RTI (complications) and mortality);
 ► adverse effects of antibiotic use (eg, nausea and 
diarrhoea);
 ► adverse effects of the intervention strategy (eg, 
increased consultation times of physicians);
 ► the costs of healthcare services, programmes and 
(dispensing) medication; healthcare utilisation (eg, 
length of consultations and tests ordered);
 ► consultation rates: reconsultation rates including 
reconsultations due to deterioration of original 
infection (eg, unplanned revisits within 2–3 weeks of 
first consultation) and due to new RTI episodes;
 ► patient outcome (eg, symptom severity, symptom 
resolution, disease duration and time to resume 
school or work);
 ► patients’ and clinicians’ knowledge about antibiotic 
use;
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 ► patients’ participation rate in decision-making about 
antibiotic use;
 ► patient satisfaction with care;
 ► quality of patient–healthcare provider 
communication.
Depending on the number of reviewers available in 
our team, we may also assess the secondary outcomes for 
studies of campaigns and regulatory interventions (eg, 
antibiotic resistance, types and rates of medical compli-
cations, the costs of healthcare services, programmes and 
(dispensing) medication, and healthcare utilisation).
Other outcomes of interest
Quality of life, use of non-antibiotic medication (eg, over-
the-counter medicines), sustainability of interventions 
(ie, change in the prescribing pattern over a period after 
the delivery of interventions), physicians’ and patients’ 
views and attitudes towards antibiotic prescribing.
Feasibility and acceptability
Secondary outcomes
For patient-targeted and clinician-targeted interven-
tions, the feasibility and acceptability of interventions 
to improve the quality of antibiotic prescribing and use 
measured as, for example, satisfaction with the interven-
tion or uptake of interventions.
Types of studies
For healthcare professional (clinicians and/or pharma-
cists) and patient-targeted interventions, we will include 
studies of prospective, comparative and experimental 
design including parallel randomised controlled trials 
(RCTs), quasi-RCTs in which the method of allocation 
is not strictly random (eg, allocation by alternation, 
date of birth and hospital number), and cluster-RCTs in 
which the method of allocation is by group (eg, patients 
of the same physician) if they: (1) evaluate the effective-
ness of interventions to improve antibiotic prescribing 
and/or use for RTIs and/or (2) evaluate the feasibility 
and acceptability of patient-targeted and clinician-tar-
geted interventions to improve antibiotic use for RTIs 
in PC general practice.
For public awareness (local, national and ‘choosing 
wisely’) campaigns40 41 and regulatory interventions, 
besides RCTs, we will also include other study designs 
(eg, non-RCTs, before and after studies with or without 
a contemporary control group) if they evaluate the effec-
tiveness of interventions to improve antibiotic prescribing 
and/or use for RTIs.
If eligible, studies will be included regardless of the 
length of follow-up, publication year and country of 
origin. We aim to include studies published in English 
and other languages. We will give priority to the inclu-
sion of studies published in English. Depending on the 
number of reviewers available in our team, we will include 
studies published in languages other than English in the 
following order: Spanish, German and other languages 
(see Study selection section). We will not include 
systematic reviews and meta-analyses in this review, but we 
will use them to identify additional studies.
Types of setting
Studies carried out in the following PC settings will be 
included:
 ► in-hours (eg, paediatric and family practice clinics)
 ► out-of-hours ambulatory care.
We will exclude studies from inpatient settings.
search methods
We will design and conduct a comprehensive search 
strategy and will crosscheck it with the strategies of two 
available systematic reviews.25 27 The search strategy will 
aim to identify RCTs in humans evaluating interventions 
aiming to improve antibiotic prescribing and use. These 
will include healthcare professional and patient-targeted 
interventions, as well as public awareness campaigns 
and regulatory interventions. We will develop a search 
strategy in collaboration with an information specialist 
and will follow the PICOTS (populations, interventions, 
comparisons, timing and settings) approach. It will not 
be restricted to reporting language, population age or 
gender, publication date, country or outcomes.
We will search MEDLINE (EBSCOHost), EMBASE 
(Elsevier), the Cochrane Library (Wiley), CINHAL 
(EBSCOHost), PsychINFO (EBSCOHost) and Web of 
Science from their inception until the date of the search. 
The concepts and terminology will be considered and 
translated to fit all database searches. These may include 
‘respiratory tract infections’, ‘antibiotic’, ‘antimicrobial’, 
‘anti-bacterial/anti-infective agents’, ‘prudent/judicious 
antibiotic use’, ‘prescribers/prescribing’, ‘interventions’, 
‘strategies’, ‘stewardship’, ‘primary health care’, ‘outpa-
tients’, ‘in-hours care’ and ‘after/out-of-hours care’. The 
strategy may also include the terminology specific to 
interventions to improve antibiotic prescribing and use, 
such as ‘education’, ‘point of care’, ‘audit or feedback’, 
‘information/awareness’ campaign and ‘choosing wisely’ 
campaign. We will also search for grey literature using 
the Latin American and Caribbean Literature on Health 
Sciences (LILACS), Turning Research Into Practice 
(TRIP) database and the system for information on grey 
literature in Europe (http:// opengrey. eu/). We will iden-
tify additional publications by manually searching the 
reference lists of included studies and relevant reviews. 
We might update the searches of relevant databases 
before publication of the review to screen for further 
potentially eligible studies. Online supplementary file 2 
provides a draft of the full search strategy in Embase.
study selection
We will merge all records identified by the electronic and 
manual searches and will remove duplicate citations. We 
will prioritise the selection of studies published in English. 
Depending on the number of reviewers available in our 
team, we will also appraise the citations and publications 
of studies published in languages other than English 
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in the following order: Spanish, German and other 
languages. Two reviewers will independently screen and 
sift the title and abstract of each citation. We will obtain 
the full-text publications of citations which meet the eligi-
bility criteria, appear relevant or for which eligibility is 
not clear. The full-text publications of selected citations 
will be independently evaluated by two reviewers. The 
recommendations proposed by the Centre for Research 
in Evidence Based Practice46 will be followed in order to 
translate the abstracts of potentially relevant citations and 
full texts of eligible publications reported in languages 
other than English for appraisal. The final list of included 
studies will be confirmed and the reasons for excluding 
studies recorded. Differences in judgement of eligibility 
will be resolved by discussion or involvement of an arbi-
trator, or both.
data extraction and management
Data extraction will be conducted by one reviewer and 
verified by a second reviewer. Data from studies reported 
across more than one publication will be extracted as one 
unit. If more than one study is reported by a single publi-
cation, data will be extracted as separate studies where 
possible. Studies may be excluded at the data appraisal 
stage if it becomes apparent that they do not meet the 
inclusion criteria. If studies reported in languages other 
than English are appraised, data extraction from publi-
cations eligible for inclusion will be confirmed by a 
native speaker following translation of full text. Differ-
ences in data collection will be resolved by discussion 
or involving an arbitrator, or both. For each eligible 
study, data will be extracted and recorded as follows: 
(1) bibliographic details and descriptive study elements 
(design, care setting, number of facilities/sites, geographic 
distribution, start and end dates of study); (2) patient 
characteristics: inclusion/exclusion, age, sex, ethnicity, 
comorbidities (eg, asthma and COPD), population type 
served (eg, urban), socioeconomic (higher vs lower 
income regions), educational level, regional differences 
(eg, in a country: north vs south, deprived vs affluent and 
urban vs rural), time of year, number of randomised/
enrolled participants and withdrawals; (3) provider 
characteristics: age, gender, experience (eg, years in 
practice) and number of clinicians per site; (4) RTI char-
acteristics: type (eg, upper RTI, acute otitis media, lower 
RTI and bronchitis), diagnostic method and/or tools 
used, signs and symptoms, antibiotic therapy prescribed 
(recommended/not recommended agents, doses, dura-
tion and route of administration) and antibiotic therapy 
previously used; (5) interventions/comparators charac-
teristics: definition, description and components (tools 
used, eg, information leaflets and decision aids), inter-
ventions’ intended target (patients or patients’ parents/
carer, physicians and/or pharmacists), delivery time (eg, 
before consultation), duration and follow-up episodes 
and (6) outcome details: the value of ‘appropriateness’ 
and/or ‘inappropriateness’ that authors of eligible 
studies have adjudicated to antibiotic prescribing and/or 
use; outcome measurement tools/methods (validated or 
not), definitions and time points; the quantitative results 
for each outcome; and any qualitative statements about 
the association between the outcomes and the interven-
tion and comparison groups.
We will group together studies with similar definitions 
of appropriateness in prescribing. We will group studies’ 
interventions into distinct categories by their components 
based on proposed classification systems.26 27 Data will be 
organised by RTI type (eg, upper RTI, acute otitis media, 
lower RTI and bronchitis), care setting, population 
(with distinction by targeted participants), intervention 
and sources of variation (eg, regional differences in a 
country).
risk of bias assessment
The quality features of included studies will be assessed 
in duplicate by two independent reviewers using criteria 
forms based on established guidelines. Differences will be 
resolved by discussion or the involvement of an arbitrator, 
or both. The criteria will cover the core items related to 
the internal validity of RCTs,47 that is, methods of random 
sequence generation and concealment of allocation at 
randomisation, the use of blinding and intention-to-treat 
(ITT) analysis and similarity between groups at baseline. 
Blinding patients and clinicians may not be possible due 
to the nature of interventions. It is possible to perform 
blinded assessment of outcomes however, and to identify 
whether studies are prone to selective outcome reporting. 
Following the debate about scoring the quality of trials, 
discussed in depth by Jüni et al,48 we will not calculate a 
composite score. The validity of eligible studies will be 
determined by rating the adequacy of each core item. 
RCTs of adequate quality will be those with an adequate 
generation of random sequence, concealment of alloca-
tion (at randomisation) and blinding of outcome assessors 
based on established guidelines.47 Bias due to attrition will 
be considered as being of significant concern if there is 
a loss to follow-up of at least 20%; ITT will be considered 
adequate if authors analysed participants based on their 
original group allocation. We will describe the studies’ 
adequacy in each item with an overall judgement on the 
quality of evidence and generate summary tables with 
the quality profile of each study. For other study designs 
(eg, before and after, and non-randomised), assessment 
criteria will be based on items from the Cochrane Collab-
oration’s by Effective Practice and Organisation of Care,49 
the Newcastle-Ottawa Scale50 and Risk Of Bias In Non-ran-
domised Studies–of Interventions.51 In all studies, we will 
assess reporting criteria including the definition and 
reporting of primary and secondary outcomes, inclusion 
and exclusion criteria, ‘a-priori’ sample size calculation 
and funding sources.
data analysis
We will use the Cochrane Collaboration’s analysis soft-
ware RevMan V.5.352 for statistical analyses and will follow 
available guidelines to incorporate cluster-RCTs.47 For 
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binary data, the intervention effect will be estimated 
using the unadjusted risk ratios or ORs with 95% CI. For 
continuous data, the intervention effect will be estimated 
using the weighted mean differences or standardised 
mean differences if studies use different scales. Where 
sufficient detail allows their calculation, the summary 
statistics and 95% CIs together with the exact p values 
will be reported. One single estimate of a treatment effect 
will be produced for each individual study. Data permit-
ting, outcome data will be combined and meta-analyses 
will be incorporated where appropriate (ie, two or more 
studies per outcome). The pooled effect estimate(s) will 
be produced using the random effects model and will 
be retained if between-study heterogeneity is substantial. 
Otherwise the fixed-effects model will be used. Available 
guidance will be used to estimate missing data.47 We will 
assess between-study heterogeneity using the I2 statistic53 
and by visual inspection of forest plots.54 Values of hetero-
geneity are represented as low (below 25%), moderate 
(50%), severe (up to 75%) and very severe (more than 
75%). We will also assess the impact of awareness and 
‘choosing wisely’ campaigns and regulatory interventions 
over time. The pooled rates of prescriptions due to RTI 
will be calculated and compared for data before and after 
(eg, 6 months) the implementation of such interventions.
We will report the results using forest plots where appro-
priate and evidence-based summary of finding tables. We 
will synthesise all results descriptively including those 
where quantitative synthesis is not appropriate.
subgroup and sensitivity analyses
If enough data are available from the studies in review, 
we will perform subgroup and sensitivity analyses for 
the primary outcomes only. We will conduct subgroup 
analyses in the following areas: (1) population and 
interventions characteristics: country (developing vs 
developed), population (children and adults aged 18 
years and older, gender, socioeconomic status and educa-
tional level, and time of year), care setting (in-hours vs 
out-of-hours care), acute RTI type, antibiotic therapy, 
diagnostic method, intervention type and intended target 
(patients and/or physicians and/or pharmacists) and (2) 
risk of bias and other methodological criteria: adequate 
(vs other), random sequence generation, allocation 
concealment and blinding attrition (lower levels: <20% vs 
higher levels: ≥20%) and ITT; study size (small: n<200 vs 
large: n≥200) and length of follow-up.
We will perform sensitivity analyses by excluding studies 
with higher risk of bias, dubious criteria for inclusion and 
unclear definitions of acute RTI. We will also exclude 
studies which do not differentiate between RTI type or 
which report unclear or incomplete definitions of appro-
priate prescribing.
ABR due to antibiotic consumption is a shared global 
health priority and most antibiotics are administered in 
PC where they are commonly used for the management 
of RTIs. Our systematic review will evaluate the interven-
tions aimed at improving the quality of prescribing and 
use of antibiotics for acute RTI. To the best of our knowl-
edge, this is the first ‘back-to-back’ systematic review on 
both (1) healthcare professional and patient-targeted 
interventions and (2) public awareness campaigns and 
regulatory interventions. The evaluation of these inter-
ventions will allow a comparison of their impact, providing 
unique information to policy-makers.
A synthesis with a broader scope including interna-
tional evidence from peer-reviewed and grey literature on 
all types of these interventions, expanded to adults and 
children, and including in-hours and out-of-hours care 
has never been performed. In addition, our search will 
have no language restrictions, thus allowing the identi-
fication of evidence from non-English literature. This 
could provide valuable findings. The results will provide 
estimates of the effectiveness, as well as the feasibility and 
acceptability of such interventions, with an assessment 
of the methodological quality of the included studies. A 
thorough search in a large number of sources will enable 
a comprehensive identification and assessment of data. 
The evidence in this review may be limited by the quality 
of studies and the significant heterogeneity of the results, 
and this may challenge the interpretation of results. We 
expect, however, that the review will produce a compre-
hensive and up-to-date evidence-based body of knowledge 
about the interventions which provide the most benefits 
towards more judicious antibiotic prescribing and use. 
This would ultimately help improve ABR. The results 
may help design future interventions and will be of inter-
national interest to public health, primary healthcare 
professionals, policy-makers and patients.
regIstratIon and publIshIng
This systematic review protocol is registered on the 
International Prospective Register of Systematic 
Reviews (http://www. crd. york. ac. uk/ PROSPERO/): 
CRD42017035305. The reporting of the review will follow 
the PRISMA checklist,55 and the review findings will be 
published in peer-reviewed journals.
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